GE HealthCare Technologies Inc. GEHC

Healthcare SIC 3844 - X-Ray Apparatus & Tubes & Related Irradiation Apparatus NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Irradiation Apparatus Manufacturing derived Nasdaq

GE HealthCare Technologies Inc. ("GE HealthCare," the "Company," "our," "us," or "we") is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. We have approximately 54,000 colleagues dedicated to our purpose to create a world where healthcare has no limits. Serving patients and providers for nearly 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine to help clinicians deliver more personalized, precise patient care. This is complemented by our broad service capabilities and dedication to quality and integrity with a strong operational culture, supported by our lean business system, Heartbeat.

Last close 71.45 2026-10-23
Market cap $32.50B 2026-03-31 share count
52-week range 58.75 - 89.77

Valuation FY2025 figures against the last close

P/S1.6x
P/E15.7x
P/FCF21.6x
EV/EBITDA12.5x
Dividend yield0.2%
Diluted EPS4.55

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • All other countries
  • United States
  • China
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 All other countries, FY2025: 9.4B (45.7%) 46% All other countries United States, FY2025: 9.2B (44.4%) 44% United States China, FY2025: 2B (9.8%) 10% China FY2024 All other countries, FY2024: 8.9B (45.3%) 45% United States, FY2024: 8.6B (43.8%) 44% China, FY2024: 2.1B (10.9%) 11% FY2023 All other countries, FY2023: 8.8B (44.8%) 45% United States, FY2023: 8.2B (42.1%) 42% China, FY2023: 2.6B (13.1%) 13%
Region FY2025FY2024FY2023
All other countries $9.43B $8.92B $8.76B
United States $9.17B $8.62B $8.23B
China $2.03B $2.13B $2.56B

As the company reported it, from the “SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Revenues by Geographic Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Revenue $20.62B$19.67B$19.55B$18.34B$17.59B—
Gross profit $8.25B$8.21B$7.92B$7.18B$7.17B—
R&D $1.26B$1.31B$1.21B$1.03B$816.0M—
SG&A $4.22B$4.27B$4.28B$3.63B$3.56B—
Total operating expenses $5.49B$5.58B$5.49B$4.66B$4.38B—
Operating income $2.76B$2.62B$2.44B$2.52B$2.79B—
Pre-tax income $2.77B$2.58B$2.36B$2.51B$2.88B—
Income tax $614.0M$531.0M$743.0M$563.0M$600.0M—
Net income $2.08B$1.99B$1.57B$1.92B$2.25B—
EPS, basic 4.564.373.054.224.95—
EPS, diluted 4.554.343.034.224.95—
Shares, diluted (wtd. avg.) 458.0M459.0M458.0M454.0M454.0M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $4.49B$2.87B$2.51B$1.45B$561.0M$1.01B
Inventory $2.23B$1.94B$1.96B$2.15B——
Total current assets $12.50B$9.90B$9.41B$8.32B——
Property, plant and equipment ——$2.14B$2.00B——
Goodwill $13.49B$13.14B$12.94B$12.81B$12.89B—
Other intangibles $1.13B$1.08B$1.25B$1.52B——
Total assets $36.91B$33.09B$32.45B$27.54B——
Accounts payable $3.25B$3.04B$2.95B$2.94B——
Short-term debt $502.0M$1.50B$1.00B$15.0M——
Total current liabilities $9.11B$9.55B$8.98B$7.19B——
Long-term debt $9.49B$7.45B$8.44B$8.23B——
Total liabilities $26.31B$24.44B$25.14B$17.95B——
Retained earnings $5.28B$3.26B$1.33B$0——
Total equity $10.38B$8.45B$7.14B$9.36B$16.68B$14.75B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow $1.99B$1.96B$2.10B$2.13B$1.61B—
Depreciation and amortisation $287.0M$268.0M$248.0M$228.0M$225.0M—
Stock-based compensation $130.0M$125.0M$114.0M$67.0M$76.0M—
Capital expenditure $482.0M$401.0M$387.0M$310.0M$248.0M—
Investing cash flow -$1.05B-$914.0M-$558.0M-$398.0M-$1.76B—
Financing cash flow $617.0M-$573.0M-$478.0M-$822.0M-$263.0M—
Dividends paid $64.0M$55.0M$41.0M$0$0—
Buybacks $200.0M$0$0———

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001932393-26-000007.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 10B 20B 30B Revenue, FY2021: 17.6B Gross profit, FY2021: 7.2B Net income, FY2021: 2.2B Revenue, FY2022: 18.3B Gross profit, FY2022: 7.2B Net income, FY2022: 1.9B Revenue, FY2023: 19.6B Gross profit, FY2023: 7.9B Net income, FY2023: 1.6B Revenue, FY2024: 19.7B Gross profit, FY2024: 8.2B Net income, FY2024: 2B Revenue, FY2025: 20.6B Gross profit, FY2025: 8.2B Net income, FY2025: 2.1B FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $17.59B $18.34B $19.55B $19.67B $20.62B
Gross profit — $7.17B $7.18B $7.92B $8.21B $8.25B
Net income — $2.25B $1.92B $1.57B $1.99B $2.08B

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3844

TickerCompanyMarket capP/ERevenue growth
BFLY Butterfly Network, Inc. $1.77B — 19.0%
PHG KONINKLIJKE PHILIPS NV — — —
MBAI Check-Cap Ltd — — —
NNOX Nano-X Imaging Ltd. — — 15.4%